To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

Learn more about:
Related Clinical Trial
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss Anti-Androgen Treatment for COVID-19 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss The Effect of Platelet Rich Plasma on Non-scarring Alopecia Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter HairDx Analytical Validation Study The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study To Evaluate the Pharmacokinetics and Safety of AD-208 The Utility of Platelet Rich Plasma in Hair Loss Computer-Assisted Versus Manual Hair Harvest Comparative Study Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) PAI-1 Expression in Non-scarring Hair Loss Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Cold Plasma to Treat Hair Loss Adipose-derived SVF for Treatment of Alopecia Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Photosensitization Study in Androgenetic Alopecia Point-of-Care Adipose-derived Cells for Hair Growth Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Modulated Light Therapy in Participants With Pattern Hair Loss Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia N-Acetyl-Cysteine for Treatment of AGA in Men Clinical Trial in Females for Female Pattern Hair Loss Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Treatment of Androgenetic Alopecia in Males and Females Microarray Analysis of Scalp Biopsies After Minoxidil Treatment Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Minoxidil Response Testing in Males With Androgenetic Alopecia Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Treatment of Androgenetic Alopecia in Females, 9 Beam Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Treatment of Androgenetic Alopecia in Males Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Treatment of Androgenetic Alopecia in Females, 12 Beam Nanofat Grafting for Treatment of Androgenetic Alopecia Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Treatment of Androgenic Alopecia in Males A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Androgenetic Alopecia and the JAK-STAT Pathway Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Brief Title

To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

Official Title

A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers

Brief Summary

      The trial is a multicentre, randomised, double-blind, placebo controlled phase 2 trial.

      60 healthy bald male subjects diagnosed with alopecia, who are between 18 and 55 years old
      and provide written informed consent will be eligible for inclusion.

      The trial period will consist of a screening period of up to 3 weeks followed by 12 weeks of
      dosing, three times per week. Each subject will receive two doses of the five trial treatment
      doses (placebo, 0.00625, 0.025, 0.050, and 0.100 μg respectively). The doses will be given as
      intradermal injections. On each volunteer, two treatment areas will be placed on the head and
      the two selected doses will be allocated to the respective treatment areas according to the
      randomisation scheme. The treatment areas will be selected on the border between the bald
      surface and the surface with hair.

      The effect on hair growth will be measured at week 8 and 12
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

To evaluate the efficacy of FOL-005 on scalp hair density


Condition

Androgenic Alopecia

Intervention

FOL-005

Study Arms / Comparison Groups

 0.00625 μg FOL-005
Description:  0.00625 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

60

Start Date

March 5, 2018

Completion Date

August 30, 2018

Primary Completion Date

August 30, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Healthy male, aged 18-55 years

          -  Androgenetic alopecia (AGA)) - Norwood/Hamilton grade 3V to 4/4a

          -  Caucasian, skin type I - IV according to Fitzpatrick's classification

        Exclusion Criteria:

          -  Any dermatological disorders of the scalp which might interfere with the application
             of Investigational Medical Product or examination method, such as fungal or bacterial
             infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy

          -  Any skin pathology (e.g. scar, nevus) or general condition (e.g. uncontrolled thyroid
             diseases) that in the investigator's opinion can interfere with the evaluation of the
             treatment areas or requires topical or systemic therapy

          -  History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen
             effluvium or conditions other than androgenetic alopecia

          -  Immunological disorders such as alopecia areata, and systemic lupus erythematosus and
             other systemic known autoimmune disorders

          -  Diabetes mellitus

          -  Coagulation deficiencies

          -  Topical treatments for hair growth (minoxidil, anti-androgens or other agents known to
             affect hair growth) in the last 6 months

          -  Topical treatments of the scalp including corticosteroids, tacrolimus, retinoids in
             the last 2 months or other treatments that may affect hair growth

          -  Platelet rich plasma (PRP) treatment on scalp during the last 12 months

          -  Systemic therapy using retinoids, cyclosporine within the last 3 months

          -  Systemic treatment with beta blockers or corticosteroids, scalp procedures e.g.
             surgery, laser, light, micro-needling within the last 6 months

          -  Finasteride (e.g. Propecia®) or Dutasteride intake in the last 12 months, or any
             systemic hair therapy medication in the last 12 months

          -  History of any acute (e.g. acute infections) or chronic illness (e.g. psoriasis,
             atopic dermatitis, porphyria) or known skin cancer that in the opinion of the
             investigators might confound the results of the trial

          -  History or clinical signs of keloids or hypertrophic scars

          -  Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening

          -  Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g.
             Pentoxifylline, nitroglycerine) or anticoagulating drugs (e.g. heparins, cumarins, new
             oral anticoagulants, regular intake of acetylsalicylic acid)

          -  Current or within 3 months prior to first dosing use of anti-inflammatory medication
             (ibuprofen, paracetamol is permitted), corticosteroids (nose drops, eye drops and/or
             inhalers are permitted) or immunosuppressive drugs taken for more than 2 consecutive
             weeks

          -  Hair transplantation at any time
      

Gender

Male

Ages

18 Years - 55 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT03467412

Organization ID

FCS-002


Responsible Party

Sponsor

Study Sponsor

Follicum AB

Collaborators

 Bioskin GmbH

Study Sponsor

, , 


Verification Date

March 2018